source
- Novartis halts CD19 CAR-T trial after three deaths, Bristol Myers also pauses similar programNovartis announced a pause to its CD19-directed CAR-T cell therapy trials after three patients experienced fatal immune reactions. The company said the deaths were linked to a severe cytokine relea…
- FDA greenlights Takeda and Protagonist's rusfertide (Mimrylo) for polycythemia veraThe U.S. Food and Drug Administration has granted approval to rusfertide, a therapy developed jointly by Takeda Pharmaceutical and Protagonist Therapeutics. The drug, to be marketed under the name…